OR WAIT null SECS
May 11, 2022
Further development of nucleic acid-based therapeutics has been accelerated by the recent success of mRNA vaccines.
May 02, 2022
Complex hurdles complicate the development of emerging therapies.
Plant-based manufacturing technology gains mainstream edge in biopharmaceutical production.
April 22, 2022
Catalent will invest $350 million into integrated biologics drug substance and drug product manufacturing at Bloomington, Indiana facility.
April 02, 2022
The recent success of mRNA vaccines has opened the door for further and future development of nucleic acid-based therapies.
March 09, 2022
Spectrum Chemical has further expanded its bioCERTIFIED product portfolio to support the growing global demand for new vaccines and therapeutics.
March 02, 2022
The use of bioengineering offers practical tools for the evolution of host cells.
March 01, 2022
Capacity concerns and regulatory compliance considerations will drive the decision about outsourcing the manufacture of clinical trial materials.
February 21, 2022
Recipharm has strengthened its biologics manufacturing capabilities with the acquisition of both Vibalogics and Arranta Bio.
February 17, 2022
Thermo Fisher Scientific is expanding its Millersburg, Penn., site with a $40 million investment to support increased production of single-use technology for critical vaccines and biologics.